An Experimental Investigation of Masking in the US FDA Adverse Event Reporting System Database

被引：0
|
作者：
Hsin-wei Wang
Alan M. Hochberg
Ronald K. Pearson
Manfred Hauben
机构：
[1] Computational Sciences Centre of Emphasis,Risk Management Strategy
[2] Pfizer Global Research and Development,undefined
[3] ProSanos Corporation,undefined
[4] Pfizer Inc.,undefined
[5] New York University School of Medicine,undefined
[6] New York Medical College,undefined
[7] Brunel University,undefined
来源：
Drug Safety | 2010年 / 33卷
关键词：
Adverse Event Reporting System; Spontaneous Reporting System; Drug Removal; Pharmaceutical Company Database; Disproportionality Analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: A phenomenon of ‘masking’ or ‘cloaking’ in pharmacovigilance data mining has been described, which can potentially cause signals of disproportionate reporting (SDRs) to be missed, particularly in pharmaceutical company databases. Masking has been predicted theoretically, observed anecdotally or studied to a limited extent in both pharmaceutical company and health authority databases, but no previous publication systematically assesses its occurrence in a large health authority database.
引用
收藏
页码：1117 / 1133
页数：16
相关论文
共 50 条
  • [1] An Experimental Investigation of Masking in the US FDA Adverse Event Reporting System Database
    Wang, Hsin-wei
    Hochberg, Alan M.
    Pearson, Ronald K.
    Hauben, Manfred
    [J]. DRUG SAFETY, 2010, 33 (12) : 1117 - 1133
  • [2] Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database A Disproportionality Analysis
    Shamloo, Behrooz K.
    Chhabra, Pankdeep
    Freedman, Andrew N.
    Potosky, Arnold
    Malin, Jennifer
    Smith, Sheila Weiss
    [J]. DRUG SAFETY, 2012, 35 (06) : 507 - 518
  • [3] Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database
    Poluzzi, Elisabetta
    Raschi, Emanuel
    Koci, Ariola
    Moretti, Ugo
    Spina, Edoardo
    Behr, Elijah R.
    Sturkenboom, Miriam
    De Ponti, Fabrizio
    [J]. DRUG SAFETY, 2013, 36 (06) : 467 - 479
  • [4] Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database
    Elisabetta Poluzzi
    Emanuel Raschi
    Ariola Koci
    Ugo Moretti
    Edoardo Spina
    Elijah R. Behr
    Miriam Sturkenboom
    Fabrizio De Ponti
    [J]. Drug Safety, 2013, 36 : 467 - 479
  • [5] ‘Extreme Duplication’ in the US FDA Adverse Events Reporting System Database
    Manfred Hauben
    Lester Reich
    James De Micco
    Katherine Kim
    [J]. Drug Safety, 2007, 30 : 551 - 554
  • [6] Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database
    Morris, Robert
    Ali, Rahinatu
    Cheng, Feng
    [J]. CURRENT DRUG TARGETS, 2024, 25 (07) : 454 - 464
  • [7] Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones A Disproportionality Analysis of the US FDA Adverse Event Reporting System Database
    Motola, Domenico
    Piccinni, Carlo
    Biagi, Chiara
    Raschi, Emanuel
    Marra, Anna
    Marchesini, Giulio
    Poluzzi, Elisabetta
    [J]. DRUG SAFETY, 2012, 35 (04) : 315 - 323
  • [8] Cardiovascular, Ocular and Bone Adverse Reactions Associated with ThiazolidinedionesA Disproportionality Analysis of the US FDA Adverse Event Reporting System Database
    Domenico Motola
    Carlo Piccinni
    Chiara Biagi
    Emanuel Raschi
    Anna Marra
    Giulio Marchesini
    Elisabetta Poluzzi
    [J]. Drug Safety, 2012, 35 : 315 - 323
  • [9] Differences in Anaphylaxis Reporting Among Cephalosporins: Analysis of the FDA Adverse Event Reporting System Database
    Shah, Divya
    Stone, Cosby
    Rukasin, Christine
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB77 - AB77
  • [10] Novel adverse events of blonanserin: a disproportionality analysis in the FDA Adverse Event Reporting System database
    Subeesh, Viswam
    Singh, Hemendra
    Maheswari, Eswaran
    Beulah, Thomas
    [J]. MINERVA PSICHIATRICA, 2018, 59 (02): : 105 - 110
12345